

Alma Mater Studiorum Università di Bologna
Archivio istituzionale della ricerca

Localization of the 5-hydroxytryptamine 4 receptor in equine enteric neurons and extrinsic sensory fibers

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version:

Giancola, F., Rambaldi, A.M., Bianco, F., Iusco, S., Romagnoli, N., Tagliavia, C., et al. (2017). Localization of the 5-hydroxytryptamine 4 receptor in equine enteric neurons and extrinsic sensory fibers. *NEUROGASTROENTEROLOGY AND MOTILITY*, 29(7), 1-12 [10.1111/nmo.13045].

Availability:

This version is available at: <https://hdl.handle.net/11585/615914> since: 2018-01-16

Published:

DOI: <http://doi.org/10.1111/nmo.13045>

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>).
When citing, please refer to the published version.

(Article begins on next page)

This is the final peer-reviewed accepted manuscript of:

Giancola, F., Rambaldi, A.M., Bianco, F., Iusco, S., Romagnoli, N., Tagliavia, C., Bombardi, C., Clavenzani, P., De Giorgio, R., Chiocchetti, R., 2017. *Localization of the 5-hydroxytryptamine 4 receptor in equine enteric neurons and extrinsic sensory fibers*. Neurogastroenterology & Motility 29, e13045.

The final published version is available online at:

<https://doi.org/10.1111/nmo.13045>

Rights / License:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<https://cris.unibo.it/>)

When citing, please refer to the published version.

Localization of the 5-hydroxytryptamine 4 receptor in equine enteric neurons and extrinsic sensory fibers

F. Giancola^{1,2}, A. M. Rambaldi¹, F. Bianco^{1,2}, S. Iusco¹, N. Romagnoli¹, C. Tagliavia¹, C. Bombardi¹, P. Clavenzani¹, R. De Giorgio², R. Chiocchetti¹

¹Department of Veterinary Medical Sciences
(UNI EN ISO 9001:2008), University of
Bologna, Bologna, Italy

²Department of Medical and Surgical
Sciences, University of Bologna, Bologna, Italy

Correspondence:

Prof. Roberto Chiocchetti, DVM, PhD,
Department of Veterinary Medical Sciences,
University of Bologna, Bologna, Italy.
Email: roberto.chiocchetti@unibo.it

Funding information

This work was partly supported by the Italian Ministry of Public Health (Ricerca Finalizzata RER2009 -Ita-MNGIE), the Italian Ministry of University and Research (PRIN/COFIN 2009MFSXNZ_002), the Telethon grant GGP15171 to RDG, and “Fondazione del Monte di Bologna e Ravenna,” Bologna, Italy to RDG and PC.

Abstract

Background

Serotonin plays a pivotal role in regulating gut motility, visceral sensitivity, and fluid secretion via specific receptors. Among these receptors, 5-HT₄ exerts a prominent control on gut motor function. Although the prokinetic effect exerted by 5-HT₄ agonists is well known, the cellular sites of 5-HT₄ expression remain poorly understood in large mammals, e.g., horses. In this study, we evaluated the distribution of 5-HT₄ in the horse intestine and in foals with enteric aganglionosis, reminiscent of human Hirschsprung's disease.

Methods

The intestine and spinal ganglia were obtained from three healthy horses and two foals with hereditary ileocolonic aganglionosis. Tissues were processed for immunohistochemistry using a specific antibody to 5-HT₄ and a variety of neuronal markers. Myenteric and submucosal plexus 5-HT₄-immunoreactive (IR) neurons were quantified as relative percentage (mean±SD) to the total number of neurons counted. Furthermore, the density of 5-HT₄-IR nerve fibers was evaluated in the mucosa and *tunica muscularis*.

Key Results

40 The 5-HT₄ immunoreactivity was localized to large percentages of myenteric neurons ranging from
41 28±9% (descending colon) to 63±19% (ileum), and submucosal neurons ranging from 54±6%
42 (ileum) to 68±14% (duodenum). The 5-HT₄-immunoreactivity was co-expressed by some substance
43 P-IR (SP-IR) spinal ganglion neurons and extrinsic sensory fibers of aganglionic foals.

44 **Conclusions** **&** **Inferences**
45 The presence of 5-HT₄ in many enteric and extrinsic sensory neurons and nerve fibers provides solid
46 morphological evidence of the cellular sites of 5-HT₄ expression in horses. The evidence of SP-IR
47 sensory neurons positive for 5-HT₄ suggests its role in visceral sensitivity.

48 **Abbreviations:** ChAT, choline acetyltransferase; CML, circular muscle layer; CNS, central ner-
49 vous system; ECs, enterochromaffin cells; ENS, enteric nervous system; GI, gastrointestinal;
50 HuC/HuD, human neuronal protein; IPANs, intrinsic primary afferent neurons; IR, immunore-
51 active; LML, longitudinal muscle layer; LWFS, lethal white foal syndrome; MP, myenteric
52 plexus; nNOS, neuronal nitric oxide synthase; RT, room temperature; SMP, submucosal
53 plexus; SP, substance P; VIP, vasoactive intestinal polypeptide; WB, Western blot.

54 1 Introduction

55 Serotonin, or 5-hydroxytryptamine (5-HT), is a crucial transmitter controlling different functions in
56 the central (CNS) and peripheral nervous system, including the enteric nervous system (ENS).¹ About
57 95% of serotonin synthesis occurs in enterochromaffin cells (ECs) of the gut mucosal layer^{1, 2} and a
58 further minor component is synthesized in neurons of the myenteric plexus (MP).^{3, 4} The importance
59 of serotonin in gastrointestinal (GI) physiology and pathophysiology is due to its dual action as a
60 mucosal messenger and neurotransmitter.^{5, 6} Mechanical and chemical stimuli in the gut lumen are
61 able to induce ECs to release serotonin in the *lamina propria*,² which acts on specific receptors
62 expressed by mucosal projections of extrinsic primary afferent neurons; thereby, leading to sensory
63 transmission of nausea, discomfort, and pain to the CNS.^{1, 7} Serotonin has a direct effect on the
64 intramural innervation; in fact, ENS submucosal intrinsic primary afferent neurons (IPANs) and MP
65 neurons respond to serotonin signaling initiating peristaltic and secretory reflexes.^{1, 3} Serotonin
66 produced by MP neurons^{3, 4} is involved in GI motility patterns by regulating fast and slow
67 neurotransmission.^{1, 8}

68 The variety of effects mediated by serotonin in the body is determined by the activation of different
69 pathways, depending on the type of serotonin receptors involved.⁹

70 Among the serotonin receptor types, 5-HT₄ exerts a crucial role in controlling gut motility.^{10, 11} The
71 activation of 5-HT₄ is known to evoke the release of acetylcholine (and other messengers, e.g.,
72 substance P [SP]) from motor neurons of the MP resulting in a prokinetic effect in the gut.
73 Furthermore, 5-HT₄ stimulation contributes to enteric fluid secretion and probably plays a role in
74 visceral sensitivity. 5-HT₄ agonists have been used in the clinical arena to counteract motor function
75 abnormalities observable in functional bowel disorders because of the prominent prokinetic effect.
76 From this, different 5-HT₄ agonists have been developed and used in humans as prokinetic agents for
77 the treatment of chronic constipation.¹² Among them, a selective 5-HT₄ full agonist, prucalopride,^{8,}
78 ¹³ stimulates intestinal propulsion, mucosal secretion,¹⁴ and exhibits enteric neuroprotective
79 properties.¹⁵⁻¹⁸

80 Pharmacological, electrophysiological, and molecular studies showed the presence of 5-HT₄ in
81 different intestinal cell types of rodents and humans.^{8, 13, 15, 16, 19-21} Concerning the
82 characterization of 5-HT₄, few studies have performed an immunohistochemical localization of the
83 cellular expression of this receptor and has mainly been carried out on mice.^{16, 22}

84 The present study has been undertaken to establish the cellular sites of 5-HT₄ expression in horses as
85 a paradigm of a large mammalian species. Indeed, 5-HT₄ seems to play a fundamental role in GI
86 physiology and seems to be a promising pharmacological target for equine GI disorders.²³⁻³³ In
87 addition, we investigated 5-HT₄ expression in visceral extrinsic sensory nerves by analyzing spinal
88 ganglion neurons from healthy horses and intestinal tissues from foals with lethal white foal syndrome
89 (LWFS), i.e., ileocolonic aganglionosis, reminiscent of Hirschsprung's disease in humans.³⁴

90 **2 Materials and Methods**

91 **2.1 Animals and tissues collection**

92 Intestinal tissue samples were collected from three horses of different breeds, aged 18 months, and
93 slaughtered at a public slaughterhouse. None had a history of GI disorders. Lumbar spinal ganglia
94 were collected from the half-carcasses. Furthermore, the ileum and pelvic flexure of two new-born
95 American paint male foals affected with LWFS were utilized.³⁴ According to Directive 2010/63/EU
96 of the European Parliament and of the Council of September 22, 2010 on the protection of animals
97 used for scientific purposes, the Italian legislation (D. Lgs. n. 26/2014) does not require any approval
98 by the competent Authorities or by ethics committees.

99 The blood samples of selected horses were analyzed and hemato-biochemical parameters confirmed
100 the general healthy state of the subjects.

101 Cryosections were obtained as described previously^{34, 35} from small and large intestine (descending
102 duodenum, jejunum, ileum, pelvic flexure, and descending colon) and spinal ganglia of three adult
103 horses and from ileum and pelvic flexure of two LWFS foals.

104 Whole-thickness pieces of pelvic flexure were immediately frozen in liquid nitrogen and stored at
105 -80°C for testing anti-5-HT₄ antiserum specificity by Western blot analysis.

106 **2.2 Immunofluorescence**

107 Cryosections were hydrated in phosphate-buffered saline (PBS) and processed for immunostaining.
108 To block non-specific bindings, the sections were incubated in a solution containing 20% normal goat
109 or donkey serum (Colorado Serum Co., Denver, CO, USA) and 0.5% Triton X-100 (Sigma Aldrich,
110 Milan, Italy, Europe) in PBS for 1 hour at room temperature (RT). The cryosections were incubated
111 overnight in a humid chamber at RT with primary antibodies (Table 1) diluted in 1.8% NaCl in
112 0.01 M PBS containing 0.1% sodium azide. Enteric neurons were identified with the anti-human
113 neuronal protein (HuC/HuD) antiserum.

114 After washing in PBS (3×10 minutes), the sections were incubated for 1 hour at RT in a humid
115 chamber with the secondary antibodies (Table 2) diluted in PBS. Cryosections were then washed in
116 PBS (3×10 minutes) and mounted in buffered glycerol at pH 8.6 with 4',6-diamidino-2-phenylindole
117 – DAPI- (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

118 **2.3 Specificity of the antibodies**

119 The polyclonal rabbit anti-5-HT₄ antibody utilized in the present research is predicted to work on
120 horse tissues as specified in the datasheet provided by the manufacturer (rabbit anti-5HT₄, AB60359;
121 Abcam, Cambridge, UK, Europe). To confirm its specificity, we tested this antibody by WB analysis.
122 The specificity of the rabbit anti-choline acetyltransferase (ChAT), neuronal nitric oxide synthase

123 (nNOS), and SP antibodies has been previously tested on horse tissues.³⁵ In the present research, we
124 also utilized the goat anti-ChAT antibody (AB144P; Millipore, Darmstadt, Germany, Europe), which
125 was co-localized with the validated antibody rabbit anti-ChAT³⁵ in neurons and nerve fibers by
126 double staining (Fig. S1).

127 The specificity of the mouse anti-vasoactive intestinal polypeptide (VIP) antibody³⁶ has not been
128 tested on horse tissues. Nevertheless, in the present research, we co-localized this antiserum with the
129 rabbit anti-VIP antibody (Sc-20727; Santa Cruz Biotechnology). The two antibodies were co-
130 localized in neurons and fibers (Fig. S2).

131 The serotonin molecule is identical in all species and the specificity of the antiserum should be similar
132 in mammals and fish.³⁷

133 The specificity of the secondary antibodies has been tested as described in a previous work.³⁵

134 **2.4 Western blotting**

135 Colonic tissue samples were collected, frozen in liquid nitrogen, and stored at -80°C . Tissue was
136 thawed and homogenized. Total protein content from human (SH-SY5Y) and murine (Neuro 2A)
137 neuroblastoma cell lines were included as positive and negative controls, respectively.¹⁸

138 Western blot analysis was performed according to a validated protocol¹⁸ and incubating membranes
139 with the primary antibody (Table 1) and related peroxidase-conjugated secondary antibody (Table 2).

140 Immunoreactive bands were visualized using chemiluminescent substrate (Pierce ECL Western
141 Blotting Substrate; Thermo Scientific, Milan, Italy, Europe). The intensity of luminescent signal was
142 acquired on a C-DiGit Chemiluminescent Western Blot Scanner using Image Studio Digits Software
143 Ver 3.1 (LI-COR Biotechnology, Cambridge, UK, Europe).

144 For 5-HT₄ antibody, a unique band of ~45 kDa (theoretical molecular weight ~44 kDa)
145 (<http://www.uniprot.org/>) was present in extracts from the descending colon and in the positive
146 control; and no band was detected in the negative control (Figure 1). Western blot analysis confirmed
147 the specificity of the primary antibody utilized in the present study.

148 **2.5 Analysis of the sections**

149 Preparations were examined on a Nikon Eclipse Ni microscope (Nikon Instruments Europe BV,
150 Amsterdam, The Netherlands, Europe) equipped with the appropriate filter cubes. The images were
151 recorded with a DS-Qi1Nc digital camera and NIS Elements software BR 4.20.01 (Nikon Instruments
152 Europe BV). Slight contrast and brightness adjustments were made using Corel Photo Paint, whereas
153 the figure panels were prepared using Corel Draw (Mountain View, Ottawa, ON, Canada).

154 **2.6 Quantification of 5-HT₄ receptor localization**

155 The proportions of neurons that were HuC/HuD-immunoreactive (IR) and that co-expressed 5-HT₄-
156 IR were quantified in each double-stained cryosections. At least 200 HuC/HuD-IR neurons were
157 counted in the MP and submucosal plexus (SMP) of each investigated gut segment/animal (n=3).
158 Data were expressed as relative percentage (mean \pm SD).

159 The quantitative analysis for the density of 5-HT₄-IR nerve fibers was performed in all intestinal
160 tracts considered. For each layer (*tunica mucosa*, circular muscle layer [CML] and longitudinal

muscle layer [LML]), three randomly selected high power fields (40×, longitudinal sections) were acquired at the same exposure time. Images were converted into an 8-bit file and were analyzed using ImageJ software (<http://imagej.nih.gov/ij/>). Threshold values were determined empirically by selecting a setting, which gave the most accurate binary image. The same threshold was used for all images. The resulting numbers of pixels corresponding to the percentage of immunoreactive area on the total area were measured. All graphical representations were prepared using commercial software (GraphPad Prism version 5.00 for Windows; GraphPad Software Inc., La Jolla, CA, USA). Data were expressed as mean±SD.

Statistical analysis has not been performed because of the small number of animals examined in the present study (n=3).

3 Results

3.1 5-HT₄ immunoreactivity in enteric neurons and nerve fibers

3.1.1 Neurons

Large percentages of HuC/HuD-IR neurons showed 5-HT₄-immunoreactivity (5-HT₄-IR) in the MP and SMP of all the GI segments under investigation (Figure 2). 5-HT₄-IR showed different degrees of brightness, varying from weak to strong. The pattern of immunoreactivity was preferentially located into the cytoplasm rather than along the plasma membrane. In the myenteric neuropil, nerve fibers and varicosities embracing neurons showed a bright 5-HT₄-IR (Figure 2A-F).

A total number of 5226 HuC/HuD-IR neurons were counted in all the intestinal tracts considered of healthy adult horses. In the MP, we counted 2595 HuC/HuD-IR neurons and 43% of these cells showed 5-HT₄-IR. In the SMP, we counted 2531 HuC/HuD-IR neurons and 63% of these cells showed 5-HT₄-IR. Considering MP and SMP together, the small and large intestine shared the same percentage of 5-HT₄-IR neurons (54%). The MP of the small and large intestine showed the same percentage (43%) of 5-HT₄-IR neurons, whereas the SMP of the small and large intestine harbored larger percentages of 5-HT₄-IR neurons (62% and 66%, respectively). In more detail, in the small intestine MP, the greatest percentage of immunoreactive neurons was observed in the ileum (63±19%) followed by duodenum (44±25%) and jejunum (35±20%). In the large intestine MP, pelvic flexure 5-HT₄-IR neurons largely outnumbered (47±13%) the density of those observed in the descending colon (28±9%) (Figure 2A-F). Submucosal neurons, which showed in general brighter 5-HT₄-IR than myenteric ones, were observed in the inner and outer SMP layers (Figure 2G-L). In the duodenal submucosa, the 5-HT₄-IR neurons were closely related to Brunner's glands (Figure 2J-L). Nevertheless, no 5-HT₄-IR nerve fibers were observed within the glands. The percentages of 5-HT₄-IR SMP neurons were similar in the pelvic flexure, duodenum, and jejunum (69±13%, 68±14%, and 67±3%, respectively), and slightly decreased in the descending colon (60±23%) and ileum (54±6%). Figure 4A graphically represents the data related to the distribution of the 5-HT₄-IR neurons.

3.1.2 Nerve fibers

Bright 5-HT₄-IR nerve fibers were widely distributed in all layers of the small and large intestine.

The mucosal layer was widely innervated by 5-HT₄-IR nerve fibers, especially in the duodenum. The 5-HT₄-IR nerve fibers were distributed in the *muscularis mucosae*,³⁸ around intestinal glands, and in the *lamina propria* (Figure 3A and D). In the mucosa of small intestine, the 5-HT₄-IR nerve fibers were more visible on the upper half of the villi, whereas in the large intestine these positive fibers were more prominent in the basal portion of the glands.

203 In the submucosa, a delicate/thin network of the 5-HT₄-IR fibers and varicosities encircled SMP
204 neurons (Figure 3E), while only a few immunoreactive fibers were visible around blood vessels.

205 In the *tunica muscularis*, the greatest density of the 5-HT₄-IR nerve fibers was observed in the CML
206 (Figure 3F) of the duodenum and descending colon. In the LML, the 5-HT₄-IR nerve fibers were well
207 represented in the descending colon and ileum and were scanty represented in the other intestinal
208 tracts. Figure 4B graphically represents the data related to the distribution of the 5-HT₄-IR nerve
209 fibers.

210 **3.2 5-HT₄ immunoreactivity in extrinsic innervation**

211 **3.2.1 Intestinal extrinsic sensory fibers**

212 In horses, most of the SP-IR innervation derives from enteric neurons supplying the CML
213 (Figure 3G).³⁴ Double immunohistochemistry carried out on adult horse tissues showed that 5-HT₄-
214 and SP-IR fibers widely co-localized (Figure S3). Notably, also in LWFS tissues, supplied only by
215 extrinsic nerves, SP-IR processes co-expressed 5-HT₄-IR (Figure 3H and I).

216 **3.2.2 Spinal ganglion neurons**

217 A weak to moderate 5-HT₄-IR was expressed by small- and medium-sized spinal ganglion neurons.
218 Double immunohistochemistry showed that the 5-HT₄R-IR neurons co-expressed SP-IR (Figure 3J-
219 N).

220 **3.3 Neurochemical coding of 5-HT₄R-IR enteric neurons**

221 In the MP, 5-HT₄-IR was expressed by excitatory neurons, detected for their immunoreactivity to
222 ChAT (Figure 5A and B) and SP (Figure 5C and D) and by inhibitory neurons, immunoreactive to
223 nNOS (Figure 5E and F). In the SMP, 5-HT₄-IR was co-expressed by large neurons co-expressing
224 SP-IR and by small putative secretomotor neurons, showing VIP-IR (Figure 5G and H). Notably,
225 subsets of myenteric and submucosal neurons showed triple co-localization 5-HT₄/SP/VIP-IRs
226 (Figure S4).

227 **3.4 5-HT immunoreactivity**

228 As expected, 5-HT-IR was strongly expressed by EC cells (Figure 6A-C). In the mucosa, 5-HT
229 positive EC cells were mainly detected in the basal portion of the *lamina propria*, in some proximity
230 to SP-IR sensory nerve fibers (Figure 6D and E).

231 **3.5 Extra-neuronal 5-HT₄-IR distribution**

232 Extra-neuronal sites of the small and large intestine of 5-HT₄-IR included smooth muscle cells of the
233 *tunica muscularis*, a subset of ECs (Figure 6A-C), and endothelial cells of small vessels (data not
234 shown). In contrast, 5-HT₄-IR was not detectable in enterocytes and interstitial cells of Cajal.

235 **4 Discussion**

236 The present study provides solid evidence of 5-HT₄-IR in the MP and SMP neurons of horse intestine.
237 Despite some functional investigations carried out on horse small and large intestine indicated the
238 presence of 5-HT₄ in the ENS of this animal model,²³⁻³³ the only immunohistochemical study

carried out on horse ENS failed to detect 5-HT₄ in enteric neurons, but confirmed the presence of this serotonergic receptor on muscular layers.³¹ Furthermore, a recent study by Delesalle et al.³⁹ questioned the presence of 5-HT₄ on cholinergic neurons of horse small intestine. In this line, our results represent strong morphological support indicating that 5-HT₄ is expressed in MP and SMP neuronal cell bodies and nerve fibers of horse GI tracts. The presence of large percentages of MP and SMP 5-HT₄-IR neurons suggests that 5-HT₄ agonists may influence both intestinal propulsion and secretion. In fact, the expression of 5-HT₄-IR by SMP SP-IR neuronal cell bodies (likely IPANs⁴⁰) and related nerve fibers supports the role of this receptor in intramural reflex activities. Once activated by 5-HT, the 5-HT₄ expressed by IPANs begins peristalsis through the recruitment of MP excitatory ChAT-/SP-IR⁴¹ and inhibitory nNOS-IR⁴² motoneurons. Our findings are consistent with Cellek et al.¹³ who showed the effect of 5-HT₄ agonists on both excitatory and inhibitory enteric neurons of the human colon.

Concerning the secretory role, it is known that the active mucosal secretion can be triggered by a serotonin-dependent activation of neurogenic responses mediated by 5-HT₄, 5-HT₃, and 5-HT_{1p} receptors expressed by intrinsic submucosal neurons. This neurogenic mechanism leads secretomotor neurons to release acetylcholine and VIP, inducing Cl⁻ and bicarbonate secretion by epithelial cells.^{10, 43} Our findings that show the co-expression of 5-HT₄-IR in SMP VIP-, and SP-IR neurons, suggest the involvement of 5-HT₄ in secretory and vasodilatory mechanisms in horses. This confirms and expands previous work by Burns and Cummings³⁸ and Moore et al.⁴⁴

In veterinary medicine, selective 5-HT₄ agonists have been not yet used as prokinetic agents to treat dysmotility disorders of the horse. The only exception is represented by the 5-HT₄ agonist mosapride which effectively attenuated the decline of small intestinal motility in an experimental model of postoperative ileus in the healthy horse. As a matter of fact, in veterinary clinical practice, the use of 5-HT₄ is still extremely limited to personal experience and, similarly to the routine practice in humans, metoclopramide, whose effects rely upon a combination of receptor interaction (i.e., dopamine receptor antagonism, 5-HT₃ antagonism and 5-HT₄ agonism), is the most commonly used.⁴⁵ While there is no evidence of side effects elicited by selective 5-HT₄ agonists, metoclopramide evokes extrapyramidal manifestations in a similar fashion to what may happen in humans chronically treated with this drug.

The expression of 5-HT₄-IR by horse spinal ganglion neurons does not necessarily indicate that these neurons contribute to the intestinal innervation; nevertheless, the presence of 5-HT₄-IR on extrinsic sensory fibers observed in aganglionic tissues of LWFS foals suggests that drugs acting on 5-HT₄ might influence the extrinsic visceral sensory pathway, as shown in humans.⁴⁶ This is the first morphological evidence of 5-HT₄-IR in the horse spinal ganglia. Splice variants of this receptor were already observed in the rat spinal ganglia.²² As 5-HT₄-IR was co-expressed by extrinsic SP-IR sensory fibers of aganglionic LWFS foals, it is plausible that this receptor might play a role in nociception.^{47, 48} In support of this notion, 5-HT₄ mRNA has been shown to be expressed by nociceptive neurons of rat spinal ganglia.^{49, 50} 5-HT₄-IR was also co-expressed by SP-negative spinal ganglion neurons, suggesting that this receptor might be involved in other aspects of the sensory function, such as mechanosensitivity. In fact, tegaserod, a 5-HT₄ partial agonist, has been shown to have an inhibitory effect on intramural mechanoreceptors of a cat rectum.⁵¹ Nevertheless, to identify and confirm a role of 5-HT₄ in the visceral sensitivity of horses, functional and pharmacological investigations are needed.

Gut vasodilation is regulated by intrinsic reflex circuitry involving SMP neurons via the activation of 5-HT₃ and 5-HT₄ receptors.⁵⁰ In the present study, endothelial cells of small vessels expressed 5-HT₄-IR. This finding is consistent with studies indicating that 5-HT₄ mRNA (together with 5-HT₁, 5-HT₂, and 5-HT₇ mRNA) is expressed by endothelial and vascular smooth muscle cells.^{52, 53}

286 Furthermore, it is known that endothelial 5-HT₄ regulates angiogenesis and that 5-HT₄ agonist
287 mosapride can inhibit proliferation and migration of endothelial cells in the human umbilical vein.⁵⁴

288 Growing evidence indicates that 5-HT₄ stimulation enhances development, survival, and
289 neurogenesis of enteric neurons^{18, 55, 56} and 5-HT₄ agonists facilitate neurogenesis from
290 transplanted stem cells in intestinal anastomosis.⁵⁷ Thus, 5-HT₄ agonists may have a
291 neuroregenerative potential that can be useful to treat horses subjected to colic surgery.

292 In conclusion, our results provide a consistent demonstration that 5-HT₄-IR is widely expressed by
293 different subsets of enteric neurons involved in secretory and motor reflexes. The morphological data
294 support previous pharmacological evidence and bear implication in the treatment of equine intestinal
295 dysmotility and constipation. Furthermore, the presence of 5-HT₄ on extrinsic nerve pathways widens
296 the role of serotonergic receptors in visceral perception mechanisms.

297 **Acknowledgments**

298 The authors are indebted with Prof. Catia Sternini of CURE Digestive Diseases Research Center,
299 Digestive Diseases Division, Departments of Medicine and Neurobiology, University of California
300 Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA, for her generous gift of the
301 anti-VIP mouse monoclonal antibody (VIP55). This work was supported by the Italian Ministry of
302 Public Health (Ricerca Finalizzata RER2009 - Ita-MNGIE), the Italian Ministry of University and
303 Research (PRIN/COFIN 2009MFSXNZ_002), the Telethon grant GGP15171 to RDG, and
304 “Fondazione del Monte di Bologna e Ravenna,” Bologna, Italy to RDG and PC.

305 **Disclosure**

306 The authors have no competing interests.

307 **Author Contribution**

308 RC, FG, RDG, and PC co-designed (conception, planning, and initiation) the study; SI and NR
309 recruited animals and defined the clinical features; SI, FG, AR, FB, CT, and CB performed the
310 experiments; RC supervised the experiments; RC, FG, and RDG analyzed the data and wrote the
311 manuscript. All authors contributed to the interpretation of the data and critically reviewed the
312 manuscript. All authors approved the final version of the manuscript.

313 **References**

- 314 1. Gershon MD, Liu MT. Serotonin and neuroprotection in functional bowel disorders.
315 *Neurogastroenterol Motil.* 2007;19(Suppl 2):19–24.
- 316 2. Spiller R. Serotonin and GI clinical disorders. *Neuropharmacology.* 2008;55:1072–1080.
- 317 3. Denes V, Wilhelm M, Nemeth A, Gabriel R. Interactions of serotonergic, cholinergic, and
318 tachykinin-containing nerve elements in the rabbit small intestine. *Anat Rec (Hoboken).* 2009;
319 292:1548–1558.
- 320 4. Keating DJ, Peiris H, Kyloh M, Brookes SJ, Spencer NJ. The presence of 5-HT in myenteric
321 varicosities is not due to uptake of 5-HT released from the mucosa during dissection: use of a novel

method for quantifying 5-HT immunoreactivity in myenteric ganglia. *Neurogastroenterol Motil.* 2013; 25:849–853.

5. De Ponti F. Pharmacology of serotonin: what a clinician should know. *Gut.* 2004; 53:1520–1535.

6. Gershon MD. Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. *Trans Am Clin Climatol Assoc.* 2012;123:268–280; discussion 280.

7. Vermeulen W, De Man JG, Pelckmans PA, De Winter BY. Neuroanatomy of lower gastrointestinal pain disorders. *World J Gastroenterol.* 2014;20:1005–1020.

8. De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT₄ receptor agonists: similar but not the same. *Neurogastroenterol Motil.* 2008;20:99–112.

9. Millan MJ, Marin P, Bockaert J, Mannoury la Cour C. Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. *Trends Pharmacol Sci.* 2008; 29:454–464.

10. Mawe GM, Hoffman JM. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. *Nat Rev Gastroenterol Hepatol.* 2013; 10:473–486.

11. Jiang C, Xu Q, Wen X, Sun H. Current developments in pharmacological therapeutics for chronic constipation. *Acta Pharm Sin B.* 2015; 5:300–309.

12. Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, pharmacokinetic, and pharmacogenomic aspects of functional gastrointestinal disorders. *Gastroenterology.* 2016;150:1319–1331.

13. Celtek S, John AK, Thangiah R, et al. 5-HT₄ receptor agonists enhance both cholinergic and nitrergic activities in human isolated colon circular muscle. *Neurogastroenterol Motil.* 2006;18:853–861.

14. Spencer NJ. Constitutively active 5-HT receptors: an explanation of how 5-HT antagonists inhibit gut motility in species where 5-HT is not an enteric neurotransmitter? *Front Cell Neurosci.* 2015;9:487.

15. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT(4) receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. *Br J Pharmacol.* 2000;131:927–932.

16. Liu M, Geddis MS, Wen Y, Setlik W, Gershon MD. Expression and function of 5-HT₄ receptors in the mouse enteric nervous system. *Am J Physiol Gastrointest Liver Physiol.* 2005;289:G1148–G1163.

17. Chetty N, Coupar IM, Tan YY, Desmond PV, Irving HR. Distribution of serotonin receptors and interacting proteins in the human sigmoid colon. *Neurogastroenterol Motil.* 2009;21:551–558, e514–555.

18. Bianco F, Bonora E, Natarajan D, et al. Prucalopride exerts neuroprotection in human enteric neurons. *Am J Physiol Gastrointest Liver Physiol.* 2016;310:G768–G775.

- 357 19. Yaakob NS, Chinkwo KA, Chetty N, Coupar IM, Irving HR. Distribution of 5-HT₃, 5-HT₄, and
358 5-HT₇ receptors along the human colon. *J Neurogastroenterol Motil.* 2015;21:361–369.
- 359 20. Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT₄ receptors located on cholinergic
360 nerves in human colon circular muscle. *Neurogastroenterol Motil.* 2005;17:366–375.
- 361 21. McLean PG, Coupar IM, Molenaar P. A comparative study of functional 5-HT₄ receptors in
362 human colon, rat oesophagus and rat ileum. *Br J Pharmacol.* 1995;115:47–56.
- 363 22. Ray AM, Kelsell RE, Houp JA, et al. Identification of a novel 5-HT(4) receptor splice variant (r5-
364 HT(4c1)) and preliminary characterisation of specific 5-HT(4a) and 5-HT(4b) receptor antibodies.
365 *Eur J Pharmacol.* 2009;604:1–11.
- 366 23. Steiner A, Roussel AJ. Drugs coordinating and restoring gastrointestinal motility and their effect
367 on selected hypodynamic gastrointestinal disorders in horses and cattle. *Zentralbl Veterinarmed A.*
368 1995;42:613–631.
- 369 24. Gerring EL, King JN. Cisapride in the prophylaxis of equine post operative ileus. *Equine Vet J*
370 *Suppl.* 1989;7:52–55.
- 371 25. van der Velden MA, Klein WR. The effects of cisapride on the restoration of gut motility after
372 surgery of the small intestine in horses; a clinical trial. *Vet Q.* 1993;15:175–179.
- 373 26. Weiss R, Abel D, Scholtysik G, Straub R, Mevissen M. 5-Hydroxytryptamine mediated
374 contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological
375 characterization of a new 5-HT(4) agonist. *J Vet Pharmacol Ther.* 2002;25:49–58.
- 376 27. Nieto JE, Snyder JR, Kollias-Baker C, Stanley S. In vitro effects of 5-hydroxytryptamine and
377 cisapride on the circular smooth muscle of the jejunum of horses. *Am J Vet Res.* 2000;61:1561–1565.
- 378 28. Lippold BS, Hildebrand J, Straub R. Tegaserod (HTF 919) stimulates gut motility in normal
379 horses. *Equine Vet J.* 2004;36:622–627.
- 380 29. Sasaki N, Okamura K, Yamada H. Effects of mosapride, a 5-hydroxytryptamine 4 receptor
381 agonist, on electrical activity of the small intestine and cecum in horses. *Am J Vet Res.*
382 2005;66:1321–1323.
- 383 30. Delco ML, Nieto JE, Craigmill AL, Stanley SD, Snyder JR. Pharmacokinetics and in vitro effects
384 of tegaserod, a serotonin 5-hydroxytryptamine 4 (5-HT₄) receptor agonist with prokinetic activity in
385 horses. *Vet Ther.* 2007;8:77–87.
- 386 31. Prause AS, Guionaud CT, Stoffel MH, Portier CJ, Mevissen M. Expression and function of 5-
387 hydroxytryptamine 4 receptors in smooth muscle preparations from the duodenum, ileum, and pelvic
388 flexure of horses without gastrointestinal tract disease. *Am J Vet Res.* 2010;71:1432–1442.
- 389 32. Prause AS, Stoffel MH, Portier CJ, Mevissen M. Expression and function of 5-HT₇ receptors in
390 smooth muscle preparations from equine duodenum, ileum, and pelvic flexure. *Res Vet Sci.*
391 2009;87:292–299.
- 392 33. Delesalle C, Deprez P, Schuurkes JA, Lefebvre RA. Contractile effects of 5-hydroxytryptamine
393 and 5-carboxamidotryptamine in the equine jejunum. *Br J Pharmacol.* 2006;147:23–35.

- 394 34. Giancola F, Gentilini F, Romagnoli N, et al. Extrinsic innervation of ileum and pelvic flexure of
395 foals with ileocolonic aganglionosis. *Cell Tissue Res.* 2016;366:13–22.
- 396 35. Russo D, Bombardi C, Grandis A, et al. Sympathetic innervation of the ileocecal junction in
397 horses. *J Comp Neurol.* 2010;518:4046–4066.
- 398 36. Wong HC, Sternini C, Lloyd K, De Giorgio R, Walsh JH. Monoclonal antibody to VIP:
399 production, characterization, immunoneutralizing activity, and usefulness in cytochemical staining.
400 *Hybridoma.* 1996;15:133–139.
- 401 37. Olsson C, Holmberg A, Holmgren S. Development of enteric and vagal innervation of the
402 zebrafish (*Danio rerio*) gut. *J Comp Neurol.* 2008;508:756–770.
- 403 38. Burns GA, Cummings JF. Neuropeptide distributions in the colon, cecum, and jejunum of the
404 horse. *Anat Rec.* 1993;236:341–350.
- 405 39. Delesalle CJCC, Van Colen I, Lefebvre RA. Clinical research abstracts of the British Equine
406 Veterinary Association Congress 2015. *Equine Vet J.* 2015;47(Suppl 48):7.
- 407 40. Furness JB. *The Enteric Nervous System.* Oxford: Blackwell Scientific Publications Ltd; 2006.
- 408 41. Malone ED, Kannan MS, Brown DR. Evaluation of substance P as a neurotransmitter in equine
409 jejunum. *Am J Vet Res.* 2000;61:1178–1184.
- 410 42. Rakestraw PC, Snyder JR, Woliner MJ, Sanders KM, Shuttleworth CW. Involvement of nitric
411 oxide in inhibitory neuromuscular transmission in equine jejunum. *Am J Vet Res.* 1996;57:1206–
412 1213.
- 413 43. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel
414 syndrome. *J Clin Gastroenterol.* 2005;39:S184–S193.
- 415 44. Moore RM, Sedrish SA, Holmes EP, Koch CE, Venugopal CS. Role of endothelium and nitric
416 oxide in modulating in vitro responses of colonic arterial and venous rings to vasodilatory
417 neuropeptides in horses. *Can J Vet Res.* 2005;69:116–122.
- 418 45. Auer JA, Stick JA. *Equine Surgery*, 4th edn. Philadelphia, PA: Elsevier; 2012.
- 419 46. Gilet M, Eutamene H, Han H, Kim HW, Bueno L. Influence of a new 5-HT₄ receptor partial
420 agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation.
421 *Neurogastroenterol Motil.* 2014;26:1761–1770.
- 422 47. Russo D, Bombardi C, Castellani G, Chiocchetti R. Characterization of spinal ganglion neurons
423 in horse (*Equus caballus*). A morphometric, neurochemical and tracing study. *Neuroscience.*
424 2011;176:53–71.
- 425 48. Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors
426 accelerates propulsive motility and inhibits visceral hypersensitivity. *Gastroenterology.*
427 2012;142:844–854 e844.

428 49. Cardenas CG, Del Mar LP, Cooper BY, Scroggs RS. 5HT4 receptors couple positively to
429 tetrodotoxin-insensitive sodium channels in a subpopulation of capsaicin-sensitive rat sensory
430 neurons. *J Neurosci.* 1997;17:7181–7189.

431 50. Nicholson R, Small J, Dixon AK, Spanswick D, Lee K. Serotonin receptor mRNA expression in
432 rat dorsal root ganglion neurons. *Neurosci Lett.* 2003;337:119–122.

433 51. Schikowski A, Thewissen M, Mathis C, Ross HG, Enck P. Serotonin type-4 receptors modulate
434 the sensitivity of intramural mechanoreceptive afferents of the cat rectum. *Neurogastroenterol Motil.*
435 2002;14:221–227.

436 52. Machida T, Iizuka K, Hirafuji M. 5-hydroxytryptamine and its receptors in systemic vascular
437 walls. *Biol Pharm Bull.* 2013;36: 1416–1419.

438 53. Ullmer C, Schmuck K, Kalkman HO, Lubbert H. Expression of serotonin receptor mRNAs in
439 blood vessels. *FEBS Lett.* 1995;370:215–221.

440 54. Nishikawa T, Tsuno NH, Shuno Y, et al. Antiangiogenic effect of a selective 5-HT4 receptor
441 agonist. *J Surg Res.* 2010;159:696–704.

442 55. Liu MT, Kuan YH, Wang J, Hen R, Gershon MD. 5-HT4 receptor-mediated neuroprotection and
443 neurogenesis in the enteric nervous system of adult mice. *J Neurosci.* 2009;29:9683–9699.

444 56. Takaki M, Goto K, Kawahara I, Nabekura J. Activation of 5-HT4 receptors facilitates
445 neurogenesis of injured enteric neurons at an anastomosis in the lower gut. *J Smooth Muscle Res.*
446 2015;51:82–94.

447 57. Goto K, Kawahara I, Inada H, et al. Activation of 5-HT4 receptors facilitates neurogenesis from
448 transplanted neural stem cells in the anastomotic ileum. *J Physiol Sci.* 2016;66:67–76.

449

450 **TABLE 1** Details of primary antibodies used in the present study


Antibody	Immunogen	Source, cat. no., species	RRID	Dilution
HuC/HuD	Human HuC/HuD neuronal protein	Life Technologies, A21271; Mouse monoclonal; Clone 16A11	AB_221448	IHC 1:200; WB 1:200
ChAT	Peptide fragment of purified porcine ChAT (GLFSSYRLPGHTQDTLVAQKSS) aminoacids:168-189	Generous gift of M. Schemann, Technische Universität München; Rabbit polyclonal; Clone P3YEB	AB_2314176	IHC 1:250
ChAT	Human placental enzyme	Millipore, AB144P; Goat polyclonal	AB_90661	IHC 1:25
5-HT ₄ R	Synthetic peptide: LMAILGNLLVMVAVCWDRQLRKIKTNYFIVSLAFADLLVS, corresponding to amino acids 31-70 of Human 5HT ₄ Receptor	Abcam, AB60359; Rabbit polyclonal	AB_2122438	IHC 1:200; WB 1:200
nNOS	Amino acids 2-300 of human NOS1	Santa Cruz, (A-11) sc-5302; Mouse monoclonal	AB_626757	IHC 1:50
Substance P	Substance P-BSA conjugate	Fitzgerald, 10-S15A; Rat monoclonal; Clone MO9205, Batch 115	AB_1288870	IHC 1:400
VIP55		CURE/DDR C; Mouse monoclonal; Clone #55		IHC 1:2500
VIP	Amino acids 1-95 of human VIP	Santa Cruz, Sc-20727; Rabbit polyclonal	AB_2304501	IHC 1:50

Suppliers: Abcam, Cambridge, UK, Europe; CURE/DDRC, DDD, University of California Los Angeles, Los Angeles, CA, USA; Fitzgerald Industries Int., Inc. Concord, MA, USA; Life Technologies, Carlsbad, CA, USA; Merck Millipore, Merck KGaA, Darmstadt, Germany, Europe; Santa Cruz Biotechnology, Santa Cruz, CA, USA. 5-HT₄R, 5-hydroxytryptamine receptor 4; ChAT, choline acetyltransferase; HuC/HuD, human neuronal protein; IHC, Immunohistochemistry; nNOS, neuronal nitric oxide synthase; RRID, Research Resource Identifiers; SP, Substance P; VIP, vasoactive intestinal polypeptide; WB, Western blot.

Table 2. Details of secondary antisera used in the present study

Secondary antibody	Host species	Source	Code	Dilution
Antimouse IgG Alexa 594	Goat	Life Technologies	A11005	IHC 1:200
Antimouse IgG biotinylated ^a	Goat	Vector Laboratories	BA-9200	IHC 1:200
Antirabbit IgG FITC	Goat	Merck Millipore	401314	IHC 1:200
Antirabbit IgG HRP	Goat	Sigma Aldrich	A0545	WB 1:35000
Antirabbit IgG Alexa 594	Donkey	Abcam	AB150132	IHC 1:600
Antirat IgG Alexa 594	Donkey	Life Technologies	A21209	IHC 1:50
Antirat IgG Alexa 488	Goat	Biotium	20023	IHC 1:100
Antigoat IgG TRITC	Donkey	Jackson	705-295-003	IHC 1:100

Suppliers: Abcam, Cambridge, United Kingdom, Europe; Biotium Inc., Hayward, California, USA; Jackson ImmunoResearch Laboratories, Inc, Pennsylvania, USA; Life Technologies, Carlsbad, Ca, USA; Merck Millipore, Darmstadt, Germany, Europe; Sigma Aldrich, Milan, Italy, Europe; Vector Laboratories, Burlingame, California, USA. FITC, fluorescein isothiocyanate; HRP, horseradish peroxidase; IHC: Immunohistochemistry; TRITC, Tetramethylrhodamine; WB, Western blot.
^a Used with AMCA (Aminomethylcoumarin) streptavidine (1:100; SA-5008; Vector Laboratories).



468

469 **Figure 1**

470 Validation of 5-HT₄ antibody in horse tissue by Western blot. Total protein lysate from horse colon
 471 (lane 1), marker of molecular weight (M) (lane 2), SH-SY5Y human cell line as positive control (lane
 472 3), murine Neuro2A (N2A) cell line as negative control (lane 4). A specific band of ~45 kDa was
 473 detected in horse tissue (lane 1) and in the positive control (lane 3). No bands were detected in the
 474 negative control (lane 4)




Figure 2

Micrographs showing HuC/HuD- and 5-HT₄-immunoreactivity (IR) in tangential cryosections of myenteric and submucosal plexus of horse ileum (A-C), pelvic flexure (D-F), and duodenum (J-L). (A-F) Stars indicate some HuC/HuD-IR myenteric plexus neurons of the ileum (A-C) and pelvic flexure (D-F) which showed 5-HT₄-IR. Arrows indicate nerve fiber varicosities showing strong 5-HT₄-IR. (G-L) Stars indicate some ileal and duodenal submucosal plexus HuC/HuD-IR neurons co-expressing 5-HT₄-IR. (G-I) The open arrow indicates one 5-HT₄-IR ileal submucosal neuron showing very faint HuC/HuD-IR. HuC/HuD-IR showed several degrees of immunoreactivity, from strong nuclear and cytoplasmic immunoreactivity to very weak (or almost undetectable). Bars = A-C; G-L: 20 μm; D-F: 100 μm




Figure 3

(A-F) Micrographs showing 5-HT₄-immunoreactive nerve fibers (arrows) in the *lamina propria* (A-C, D), *muscularis mucosae* (E) and circular (CML) and longitudinal muscle layer (LML) (transverse cryosections) (F) of the horse ileum; stars (E) indicate some 5-HT₄-IR submucosal neurons very close to the *muscularis mucosae*. (G) Longitudinal ileal cryosections showing the dense CML innervation supplied by substance P (SP) nerve fibers. (H and I) Longitudinal cryosections of the ileum of a lethal white foal syndrome animals, characterized by the absence of enteric neurons. The arrows indicate SP-IR sensory fibers of extrinsic origin running between CML and LML and co-expressing strong 5-HT₄-IR. (J-O) Cryosections of horse spinal ganglion neurons; the arrows indicate SP-IR sensory neurons which co-expressed 5-HT₄-IR; stars indicate other 5-HT₄-IR neurons which were SP-negative. Bars = A-C, E, H and I: 20 μ m; D, F, G, J-L: 100 μ m




Figure 4

(A) Graphical representation of the percentages of 5-HT₄-immunoreactive (-IR) neurons in the horse small and large intestine. Black bars indicate the percentages of 5-HT₄-IR neurons in the myenteric plexus of duodenum (161/452 cells), jejunum (147/497 cells), ileum (348/571 cells), pelvic flexure (297/606 cells), and descending colon (165/469 cells). Gray bars indicate the percentages of 5-HT₄-IR neurons in the submucosal plexus (SMP) of duodenum (394/586 cells), jejunum (262/404 cells), ileum (324/599 cells), pelvic flexure (377/540 cells), and descending colon (248/402 cells). Data are represented as mean±SD. (B) Graphical representation of the density of 5-HT₄-immunoreactive nerve fibers in the *tunica mucosa* (mucosa), circular muscle layer (CML) and longitudinal muscle layer and (LML) of duodenum, jejunum, ileum, pelvic flexure, and descending colon. Data are represented as mean±SD




Figure 5

Micrographs showing the co-localization of 5-HT₄-immunoreactivity (IR) with choline acetyltransferase (ChAT), substance P (SP), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal polypeptide (VIP) in the myenteric (A-F) and submucosal plexus (G-H) of the horse ileum. (A and B) Stars indicate some myenteric plexus 5-HT₄-IR neurons co-expressing ChAT-IR. (C and D) Stars and arrows indicate myenteric plexus neurons and nerve fibers showing co-localization between 5-HT₄- and SP-IR. (E and F) Stars indicate 5-HT₄-IR myenteric plexus neurons co-expressing nNOS-IR. (G and H) Stars indicate some submucosal plexus neurons expressing strong 5-HT₄ and VIP-IR. The arrow indicates a 5-HT₄-IR neuron, which was VIP-negative. Bar = A-H: 20 μ m




Figure 6

Micrographs showing serotonin (5-HT) and 5-HT₄-immunoreactivity (IR) in the mucosa of the horse ileum. (A-C) Arrows indicate 5-HT₄-IR expressed by nerve fibers surrounding a crypt in which two enterochromaffin cells (ECs) (open arrows) co-expressed 5-HT₄- and 5-HT-IR. (D and E) Bright 5-HT-IR EC (open arrows) lining the crypts (D) and villi (E) closely located to a dense network of Substance P (SP) immunoreactive sensory nerve fibers (red color). Arrows (D) indicate two SP-IR submucosal neurons. Bar = A-E: 20 μ m